|
| Press Releases |
|
 |
|
| Thursday, June 9, 2022 |
|
|
エーザイ、2023年3月期業績予想（IFRS）の修正に関するお知らせ |
| 直近の業績の動向等を踏まえ、2022年5月13日に公表した2023年3月期（2022年4月1日から2023年3月31日）の業績予想を下記のとおり修正しますのでお知らせします。 more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
|
エーザイ、米国臨床腫瘍学会年次総会において抗体薬物複合体farletuzumab ecteribulinの最新の知見を発表 |
| エーザイ、米国臨床腫瘍学会年次総会において抗体薬物複合体farletuzumab ecteribulinの最新の知見を発表 more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
|
エーザイ、メコバラミンの高用量製剤がALSの病態及び機能障害の進行抑制を予定される効能又は効果として、厚生労働省より希少疾病用医薬品に指定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、メコバラミンの高用量製剤について、筋萎縮性側索硬化症（Amyotrophic Lateral Sclerosis: ALS）の病態及び機能障害の進行抑制を予定される効能又は効果として、厚生労働省より希少疾病用医薬品に指定されたことをお知らせします。 more info >> |
|
|
エーザイ、米国臨床腫瘍学会年次総会おけるがん領域の開発品・製品に関する発表について |
| more info >> |
|
| Tuesday, May 10, 2022 |
|
|
エーザイ、筋萎縮性側索硬化症（ALS）に対する高用量メコバラミン製剤の医師主導治験の結果を踏まえて、日本における新薬承認申請に向けた作業を開始 |
| エーザイ株式会社は、このたび、国立大学法人徳島大学の梶龍兒特命教授（主任研究者）、徳島大学大学院医歯薬学研究部臨床神経科学分野 和泉唯信教授（治験調整医師）らの研究チームが発表した、発症早期の筋萎縮性側索硬化症患者様に対する高用量メコバラミンの有効性、安全性の検証を目的とした「高用量メチルコバラミン（メコバラミン）の筋萎縮性側索硬化症に対する第III相試験-医師主導治験-」の良好な臨床試験結果を受けて、メコバラミン（開発コード：E0302）の高用量製剤について、日本におけるALSに対する新薬承認申請に向けた作業を開始しましたのでお知らせします。 more info >> |
|
|
エーザイ、抗アミロイドβ（Aβ）プロトフィブリル抗体「レカネマブ」について、米国において、迅速承認制度に基づく早期アルツハイマー病に対する生物製剤ライセンス申請の段階的申請を完了 |
| エーザイ、抗アミロイドβ（Aβ）プロトフィブリル抗体「レカネマブ」について、米国において、迅速承認制度に基づく早期アルツハイマー病に対する生物製剤ライセンス申請の段階的申請を完了 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
POWERSCHOOL HOLDINGS, INC. (PWSC): Kaplan Fox & Kilsheimer LLP Investigates POWERSCHOOL and Encourages Investors to Contact the Firm
Apr 20, 2024 11:16 HKT/SGT
|
|
|
JABIL (JBL): JABIL DISCLOSES INVESTIGATION AND PLACES CEO ON PAID LEAVE - Kaplan Fox & Kilsheimer LLP Investigates and Encourages Investors to Contact the Firm
Apr 20, 2024 10:00 HKT/SGT
|
|
|
Phish Live at Sphere: Moment Factory Harnesses Sphere's Next-Generation Technologies to Reimagine Concert Experience
Apr 20, 2024 09:00 HKT/SGT
|
|
|
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
Apr 20, 2024 01:00 HKT/SGT
|
|
|
Brawijaya University researcher develops honey-processing tech
Apr 19, 2024 23:00 HKT/SGT
|
|
|
UK's Largest EV Show Returns for 4th Edition Driving Innovation with Policy Leaders, Product Launches, and EV Innovations
Apr 19, 2024 21:03: JST
|
|
|
UK's Largest EV Show Returns for 4th Edition Driving Innovation with Policy Leaders, Product Launches, and EV Innovations
Apr 19, 2024 20:03 HKT/SGT
|
|
|
GLOBE LIFE (GL): Kaplan Fox & Kilsheimer LLP Investigates GLOBE LIFE and Encourages Investors to Contact the Firm
Apr 19, 2024 20:00 HKT/SGT
|
|
|
SMC Announces Marketing Agreement with Plato Technologies. Inc.
Apr 19, 2024 16:03 HKT/SGT
|
|
|
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
|
|
|
Prestigious titles for top developers at the 14th PropertyGuru Asia Property Awards (Singapore)
Apr 19, 2024 11:30 HKT/SGT
|
|
|
Revolutionizing Tomorrow: Uniting Visionaries at the 2024 Digital Transformation Summit Philippines
Apr 19, 2024 11:23 HKT/SGT
|
|
|
朝雲集團（06601.HK）：穩健增長與高派息策略共驅，多家頭部券商給予增持評級
Apr 19, 2024 10:24 HKT/SGT
|
|
|
22nd Edition of Cyber Security Summit: Thailand to Convene Esteemed Panel of Industry Leaders
Apr 19, 2024 10:11 HKT/SGT
|
|
|
The Rapidly Evolving Real Estate Landscape: Redefine Real Estate Summit Connects Key Players in South East Asia
Apr 19, 2024 10:11 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
